R-CHOP therapy alone for limited-stage follicular lymphoma

Tomita, Naoto; Suzuki, Taisei; Ishiyama, Yasufumi; Miyashita, Kazuho; Takahashi, Hiroyuki; Numata, Ayumi; Ito, Satomi; Motohashi, Kenji; Tachibana, Takayoshi; Takasaki, Hirotaka; Kawasaki, Rika; Hagihara, Maki; Hashimoto, Chizuko; Yamazaki, Etsuko; Taguchi, Jun; Fujimaki, Katsumichi; Sakai, Rika; Fujisawa, Shin; Motomura, Shigeki; Ishigatsubo, Yoshiaki

doi:10.1016/j.leukres.2015.03.008

Cited by 3 publications

(2 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With the application of molecular targeted drugs, the 10-year overall survival rate of patients with DLBCL with R-CHOP treatment was improved [19][20][21]. To date, R-CHOP chemotherapy is still the standard treatment for patients with DLBCL.…”

Section: Discussionmentioning

confidence: 99%

Prognostic Significance of Monocytes and Monocytic Myeloid-Derived Suppressor Cells in Diffuse Large B-Cell Lymphoma Treated with R-CHOP

Liu

et al. 2016

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: To evaluate the prognostic significance of monocytes and monocytic myeloid-derived suppressor cells (M-MDSCs) for patients with diffuse large B-cell lymphoma (DLBCL) under R-CHOP chemotherapy. Methods: Flow cytometry (FCM) was applied to measure M-MDSCs (CD14⁺ HLA-DR^low/− M-MDSCs). Results: Analysis of 144 patients with DLBCL under R-CHOP treatment showed that the 5-year overall survival rate was 61.09% (95% CI: 43.72%-72.56%) and the average survival time of patients with monocytes (%) ≥ 8% was shorter than those with monocytes (%) < 8% (P = 0.0036). Further stratified analysis suggested that the average survival time of patients with monocytes (%) ≥ 8% was shorter than patients with monocytes (%) < 8% in the moderate outcome group (R-IPI = 1, 2) (P = 0.0168) and in the poorest outcome group (R-IPI > 2) (P = 0.0397), meanwhile, there was no significant difference in survival of patients with monocytes (%) ≥ 8% compared to patients with monocytes (%) < 8% in the best outcome group (R-IPI = 0) (P = 0.3106). Both of monocytes (%) and M-MDSCs were decreased in different R-IPI groups after 4-course of R-CHOP chemotherapy (P < 0.05). Conclusion: Our results indicated that monocytes (%) and M-MDSCs combined with R-IPI may be a simple and efficient immunological index to evaluate prognosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic Significance of Monocytes and Monocytic Myeloid-Derived Suppressor Cells in Diffuse Large B-Cell Lymphoma Treated with R-CHOP

Liu

et al. 2016

Cell Physiol Biochem

View full text Add to dashboard Cite

show abstract

“…Similarly, a third study found rituximab‐containing regimens to be associated with longer PFS than any of the alternatives, including RT, although once again RT showed worse results than expected based on older and larger trials, which the authors hypothesize could be due to referral bias. Other regimens, such as RCHOP alone or radioimmunotherapy with 90‐Y‐Ibritumomab, have also been tried in small single‐centre studies but would generally not be recommended outside of clinical trials.…”

Section: Therapeutic Optionsmentioning

confidence: 99%

Treatment of localized‐stage follicular lymphoma

Sorigué

Tuset

Sancho

2018

European J of Haematology

View full text Add to dashboard Cite

Follicular lymphoma (FL) is the most common indolent lymphoma, and it most frequently presents in an advanced stage. Therapeutic considerations for advanced stage are different from those of localized-stage FL, in which radiotherapy (RT) is generally recommended. However, the available evidence suffers from shortcomings that are relatively specific to this clinical entity due to its rarity and long survival with all available treatment modalities, including that most of the existing evidence originated at a time when diagnostic classifications, staging procedures and radiotherapeutic standards were different from those available today and when anti-CD20 monoclonal antibodies were not available. Available treatment modalities include observation, systemic therapy only, RT only and RT in combination with systemic therapy. We review the evidence available with each of them and the data from present-day clinical practice studies as well as briefly discuss what diagnostic and therapeutic developments may take place in the next few years.

show abstract